{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:19:06Z","timestamp":1780694346763,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017094","name":"Department of Internal Medicine, University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CB06\/03\/0018"],"award-info":[{"award-number":["CB06\/03\/0018"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejim.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T16:26:05Z","timestamp":1749918365000},"page":"106378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study"],"prefix":"10.1016","volume":"139","author":[{"given":"Alicia","family":"Trenas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9907-8817","authenticated-orcid":false,"given":"Miguel A.","family":"P\u00e9rez-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-0890","authenticated-orcid":false,"given":"Maria-Rosa","family":"Bernal-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-076X","authenticated-orcid":false,"given":"Mar\u00eda-Dolores","family":"L\u00f3pez-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-639X","authenticated-orcid":false,"given":"Juan J.","family":"G\u00f3mez-Doblas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Dolores","family":"Mart\u00ednez-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumayma","family":"Bouarich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Garc\u00eda-Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Dolores Garc\u00eda","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-3555","authenticated-orcid":false,"given":"Ricardo","family":"G\u00f3mez-Huelgas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-8274","authenticated-orcid":false,"given":"Luis M.","family":"P\u00e9rez-Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.06.007_bib0001","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2025.06.007_bib0002","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pcad.2018.07.012","article-title":"Obesity and cardiac remodeling in adults: mechanisms and clinical implications","volume":"61","author":"Alpert","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2025.06.007_bib0003","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2025.06.007_bib0004","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cvr\/cvaa334","article-title":"Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists","volume":"117","author":"Volpe","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ejim.2025.06.007_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0006","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0007","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.06.007_bib0008","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0009","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0010","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0012","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.06.007_bib0014","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.06.007_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.recesp.2010.10.003","article-title":"Validation of the spanish version of the Kansas city cardiomyopathy questionnaire","volume":"64","author":"Com\u00edn-Colet","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.ejim.2025.06.007_bib0016","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurjhf\/hft128","article-title":"The chronic kidney disease epidemiology collaboration equation outperforms the modification of diet in renal disease equation for estimating glomerular filtration rate in chronic systolic heart failure","volume":"16","author":"Valente","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.06.007_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.rce.2020.06.005","article-title":"Medical treatment of type 2 diabetes mellitus: recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine","volume":"221","author":"Carrasco-S\u00e1nchez","year":"2021","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ejim.2025.06.007_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejim.2021.11.008","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect","volume":"96","author":"G\u00f3mez-Huelgas","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0019","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0020","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0021","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2025.06.007_bib0022","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.06.007_bib0023","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.pcd.2021.04.005","article-title":"Heart failure outcomes and glucagon-like peptide-1 receptor agonists: a systematic review of observational studies","volume":"15","author":"Alkhezi","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.ejim.2025.06.007_bib0024","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/dom.15058","article-title":"Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial","volume":"25","author":"McGuire","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2025.06.007_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314598","article-title":"Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients?","volume":"23","author":"Belli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2025.06.007_bib0026","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.06.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002477","article-title":"Clinical phenotypes in heart failure with preserved ejection fraction","volume":"5","author":"Samson","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2025.06.007_bib0028","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct Obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.06.007_bib0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dbi20-0049","article-title":"Cardiovascular effects of incretin-based therapies: integrating mechanisms with Cardiovascular outcome trials","volume":"71","author":"Ussher","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2025.06.007_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.06.007_bib0031","doi-asserted-by":"crossref","first-page":"2S20","DOI":"10.1016\/S1262-3636(17)30069-1","article-title":"The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes","volume":"43","author":"Thomas","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ejim.2025.06.007_bib0032","first-page":"zvad027","article-title":"Kinematic parameters related to functional capacity, fatigue and breathlessness during the six-minute walk test in older adults with heart failure with preserved ejection fraction","author":"Fuentes-Abolafio","year":"2023","journal-title":"Eur J Cardiovasc Nurs"},{"key":"10.1016\/j.ejim.2025.06.007_bib0033","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/jcm12010241","article-title":"Kinematic parameters that can discriminate in levels of functionality in the six-minute walk test in patients with heart failure with a preserved ejection fraction","volume":"12","author":"Fuentes-Abolafio","year":"2022","journal-title":"J Clin Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T02:23:23Z","timestamp":1756693403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"alternative-id":["S0953620525002365"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.06.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of once-daily oral semaglutide in patients with heart failure with preserved ejection fraction, type 2 diabetes and obesity: a real-world study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106378"}}